Blood Test Detects Alzheimer's Disease Early

Victor
By -
0
Here is what we know. It is unlikely that scientists will develop an effective treatment for Alzheimer's disease if they can't find a way to detect Alzheimer's early.....

By Bob DeMarco
Alzheimer's Reading Room

In order to figure out how to stop the disease, scientists need to find it early. One part of the puzzles is developing effective tests to identify Alzheimer's before it takes root.

A bit of a conundrum since most people say they don't want to know, or they don't want to be tested. Don't take my word for it, ask the people that offered free screening tests for Alzheimer's disease in November and found few takers.

I live down here in south Florida and I can tell you, you won't have trouble giving away most anything if it is free.

This is interesting research and an interesting early on finding from the Scripps Research Institute in Jupiter, Florida.


Scripps Research scientists develop groundbreaking technology to detect Alzheimer's disease

Scientists from the Florida campus of The Scripps Research Institute, have developed a novel technology that is able to detect the presence of immune molecules specific to Alzheimer's disease in patients' blood samples. While still preliminary, the findings offer clear proof that this breakthrough technology could be used in the development of biomarkers for a range of human diseases.

The study, led by Scripps Research Professor Thomas Kodadek, Ph.D., was published in the January 7, 2011 edition of the journal Cell.

Traditionally, antigens—a substance such as a protein from a virus or bacteria that stimulates an immune response—have been necessary for the discovery of antibody biomarkers. There has previously been no way to identify an antibody (a type of targeted immune molecule) without first knowing the antigen that triggers its production. The new study, however, challenges conventional wisdom and uses synthetic molecules rather than antigens to successfully detect signs of disease in patients' blood samples.

These synthetic compounds have many advantages – they can be modified easily and can be produced quickly in relatively large amounts at lower cost.

"Dr. Kodadek has conceived of a new approach for identifying antibody biomarkers of human disease that bypasses the conventional, but difficult, step of identifying the natural antigens or antigen mimics," said James M. Anderson, M.D., Ph.D., director of the National Institutes of Health (NIH) Division of Program Coordination, Planning, and Strategic Initiatives, who helps oversee the NIH Common Fund's Pioneer Award Program. "The results in the paper suggest great potential for using this approach to rapidly develop diagnostic biomarkers for a variety of significant human diseases. Such boldness to challenge conventional paradigms to achieve important scientific advances is a hallmark of the NIH Director's Pioneer Award Program, which supported much of this research."

"This study essentially puts an end to the notion that the only way to pull a potentially useful antibody from blood samples is with a specific antigen," said Kodadek. "Because the antigen identification problem has proven to be so difficult, we decided to take it out of the equation."

A Focus on the Immune System

To test the concept, Kodadek and his colleagues used comparative screening of combinatorial libraries of synthetic molecules – peptoids – against serum samples obtained from mice with a multiple-sclerosis-like condition or healthy controls. Those synthetic molecules that retained more immunoglobulin (IgG), a major type of antibody, from the blood samples of the diseased animals were identified as potential agents for capturing diagnostically useful molecules. This worked well.

The team next turned to serum samples from six Alzheimer's patients, six healthy individuals, and six Parkinson's disease patients. Three peptoids were identified that captured at least three-fold higher levels of IgG antibodies from all six of the Alzheimer's patients than any of the control or Parkinson's patients. The results showed that two of the peptoids bind the same IgG antibodies; a third binds different antibodies, resulting in at least two candidate biomarkers for the disease.

"We use these peptoids as a lure to capture the IgG antibodies," Kodadek said. "Some of these synthetic molecules recognize the antigen-binding sites of disease-specific antibodies well enough to pull them from blood samples, although they almost certainly don't bind as well as the native antigens. This ability should make it possible to short circuit the discovery of the natural antigens."
______________________________________________
The first author of the study, "Identification of Candidate IgG Antibody Biomarkers for Alzheimer's Disease through Screening of Synthetic Combinatorial Libraries," is M. Muralidhar Reddy of Opko Health Laboratories and Scripps Research.

Other authors include Rosemary Wilson and Johnnie Wilson of Opko Health Laboratories; and Steven Connell, Anne Gocke, Linda Hynan, and Dwight German of The University of Texas Southwestern Medical Center.

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, non-profit biomedical research organizations, at the forefront of basic biomedical science that seeks to comprehend the most fundamental processes of life. Scripps Research is internationally recognized for its discoveries in immunology, molecular and cellular biology, chemistry, neurosciences, autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine development. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, Scripps Research currently employs approximately 3,000 scientists, postdoctoral fellows, scientific and other technicians, doctoral degree graduate students, and administrative and technical support personnel. Headquartered in La Jolla, California, the institute also includes Scripps Florida, whose researchers focus on basic biomedical science, drug discovery, and technology development. Scripps Florida is located in Jupiter, Florida. For more information, see www.scripps.edu



Subscribe to the Alzheimer's Reading Room
Enter your email address:
Alzheimer's Disease -- Advice and Insight

Bob DeMarco is the Founder of the Alzheimer's Reading Room and an Alzheimer's caregiver. The blog contains more than 2,255 articles with more than 272,100 links on the Internet. Bob resides in Delray Beach, FL.




The Alzheimer's Action Plan
 
The Art of Dementia Care


Original content Bob DeMarco, the Alzheimer's Reading Room

Post a Comment

0Comments

Post a Comment (0)